Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Hepatitis B infects over 40 million people in India
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
The pilot plant is focused on scaling up beverage production and will support applications
To accelerate the development of next-generation radioconjugates to treat cancer
Both organisations enter into a long- term collaboration to expand patient access in India
Subscribe To Our Newsletter & Stay Updated
